We bring Development, Medical Affairs, and Commercial into sync. transforming how companies bring innovations to patients. We reduce development timelines by aligning decisions and eliminating duplication across functions, improve operational efficiency and evidence generation with integrated strategy and execution, and enable earlier, more confident market access through seamless handoffs from R&D to Commercial.
From emerging biotechs to global pharma, we work hands-on with clients navigate complexity, uphold scientific integrity, and deliver treatments to patients faster — with real-world results that stick.
Companies must reimagine internal ways of working to eliminate inefficiencies and accelerate the path from development to delivery. Cross-functional alignment, smarter decision-making, and fit-for-purpose processes are critical to reducing timelines — without compromising scientific integrity or regulatory compliance. Traditional handoffs and silos no longer meet the urgency of patient need.
Breakthrough science is outpacing traditional processes, and organizations must evolve their operations to keep up. Companies struggle to translate cutting-edge research into scalable operational capabilities at the speed and scale required for competitive advantage.
Development teams optimize for regulatory approval while Commercial teams prepare for market realities and Medical Affairs generates evidence for different audience needs. Without integration, companies face delayed launches, evidence gaps, and missed opportunities.
Companies must prepare for integrated global launches that account for market access, pricing strategies, evidence generation, and cross-functional coordination while adapting to diverse healthcare systems, cultural contexts, and evolving competitive landscapes across regions.
Companies must reimagine internal ways of working to eliminate inefficiencies and accelerate the path from development to delivery. Cross-functional alignment, smarter decision-making, and fit-for-purpose processes are critical to reducing timelines — without compromising scientific integrity or regulatory compliance. Traditional handoffs and silos no longer meet the urgency of patient need.
Breakthrough science is outpacing traditional processes, and organizations must evolve their operations to keep up. Companies struggle to translate cutting-edge research into scalable operational capabilities at the speed and scale required for competitive advantage.
Development teams optimize for regulatory approval while Commercial teams prepare for market realities and Medical Affairs generates evidence for different audience needs. Without integration, companies face delayed launches, evidence gaps, and missed opportunities.
Companies must prepare for integrated global launches that account for market access, pricing strategies, evidence generation, and cross-functional coordination while adapting to diverse healthcare systems, cultural contexts, and evolving competitive landscapes across regions.
Success in today’s environment requires seamless collaboration across Development, Medical Affairs, and Commercial. Acquis brings multi-domain fluency and a hands-on approach to connect strategy with execution, helping teams align earlier, move faster, and deliver greater impact at launch and beyond.
We optimize clinical development operations and regulatory strategy to reduce timelines while maintaining scientific integrity. Our teams strengthen research processes, enhance clinical operations, and create cross-functional alignment that accelerates decision-making from IND to approval.
Read More
We transform Medical Affairs from a support function into a strategic partner that shapes evidence generation, drives KOL engagement, and creates medical communications that serve both scientific integrity and commercial objectives throughout the product lifecycle.
Read More
We build commercial capabilities that translate scientific innovation into market success. Our approach integrates market access strategy, launch planning, and commercial operations to maximize product performance while maintaining alignment with regulatory and medical strategies.
Read More
9/10
Acquis works with 9 of the 10 largest pharma companies
30+
Drug launches
3
We deliberately focus on the 3 core pillars biopharma's strategic core
Our teams combine consultants and practitioners, bringing both strategic insight and execution experience. We understand the risk/benefit/impact tradeoffs that shape decisions and know how those decisions translate into operational reality across the development continuum.
We connect siloed teams and operationalize the strategic intent of Development, Medical Affairs, and Commercial functions. We understand the handoffs, the interdependencies, and friction points — and how to solve for them.
We don't deliver recommendations and walk away. We embed with your teams and deliver transformative results. Whether you're optimizing clinical operations or launching a global brand, we stay to build capabilities and create sustainable change.
We don't recycle playbooks. We create solutions specific to your context, whether you're a Fortune 500 pharmaceutical company optimizing complex global operations or a pre-revenue biotech building foundational capabilities.
Acquis delivers results. We engaged Acquis to drive cost savings through strategic sourcing and process improvement initiatives. They helped us meet or exceed our targets by combining strong expertise with a collaborative, flexible approach.
Pharmaceutical Company
Medical Affairs has long been hamstrung by an inability to use traditional value metrics like sales or NPV to guide investment decision making. Acquis artfully integrated our company’s technical abilities and innovative spirit with their strategic consulting, change management, and implementation capabilities to produce a practical medical impact metric and a software solution to guide investment and resourcing decisions within and across therapeutic areas – an industry first!
Fortune 500 Life Science Company
The weight loss pharmaceutical market continues to skyrocket, with the global GLP-1 agonists market expanding from $13.84 billion in 2024 to a projected $48.84 billion by 2030. Against this backdrop of market opportunity, one growing pharmaceutical company found itself at a critical inflection point, struggling to scale its operations despite remarkable commercial success.
Read More
Over the next decade, biopharma success will be determined not by the most ambitious science or the largest balance sheets, but by leadership — specifically, by companies that can navigate the industry's bifurcation and develop fluency in the Alliance Economy. Others will likely face acquisition or marginalization.
Read More
We are entering what can best be described as the Alliance Economy, an operating model defined not by linear development pipelines, but by an ecosystem of interdependent players working together to navigate the new biopharma reality.
Read More
Innovation is accelerating, biotech investment is fragmenting, and market conditions are splintering under the weight of geopolitical, economic, and regulatory disruption. The companies that once defined the top of the market are no longer guaranteed to stay there. And the old playbook — great science plus patient capital equals growth — no longer works.
Read More
Over the next decade, biopharma success will be determined not by the most ambitious science or the largest balance sheets, but by leadership — specifically, by companies that can navigate the industry's bifurcation and develop fluency in the Alliance Economy. Others will likely face acquisition or marginalization.
Read More
We are entering what can best be described as the Alliance Economy, an operating model defined not by linear development pipelines, but by an ecosystem of interdependent players working together to navigate the new biopharma reality.
Read More
Innovation is accelerating, biotech investment is fragmenting, and market conditions are splintering under the weight of geopolitical, economic, and regulatory disruption. The companies that once defined the top of the market are no longer guaranteed to stay there. And the old playbook — great science plus patient capital equals growth — no longer works.
Read More
The journey of developing a new pharmaceutical product represents one of the most complex, resource-intensive, and high-risk undertakings in modern business. This comprehensive guide examines the drug development process from initial discovery through commercialization, exploring how pharmaceutical innovators balance scientific rigor, regulatory requirements, and commercial strategy to develop new therapeutic options.
Get in touch to connect with Acquis life sciences experts
